非编码RNA作为固体瘤中受体氨酸激酶信号传递的潜在治疗标:目前的状况和未来的方向
Aysan Moeinafshar1,2, Mohammad Nouri3, Nima Shokrollahi3
1Center for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Cancer cell international
|January 10, 2024
概括
受体氨酸激酶调节性非编码RNAs (RTK-RNAs) 在调节癌症途径方面表现有前途. 需要进一步的研究,以克服它们作为癌症生物标志物和治疗药物的使用所面临的挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 受体氨酸激酶 (RTKs) 在癌症发育中至关重要.
- 非编码RNAs (nc-RNAs) 调节基因表达,包括RTKs.
- RTK-RNAs是一种参与RTK调节的nc-RNAs类.
研究的目的:
- 审查目前关于RTK-RNAs在固体瘤中的研究.
- 探索RTK-RNA作用的分子机制.
- 突出RTK-RNA疗法和生物标志物潜力的进展.
主要方法:
- 关于体外,体内和临床研究的综合文献综述.
- 分析调节RTK信号通路的分子机制.
- 评估潜在的治疗策略和生物标志物应用.
主要成果:
- 识别新型RTK-RNA及其调节作用.
- 证明RTK-RNA在调节RTK信号传递方面的潜力.
- 探索RTK-RNAs作为诊断,预后和治疗目标.
结论:
- 在固体瘤中,RTK-RNA具有作为治疗点和生物标记物的巨大潜力.
- 在开发有针对性的RTK-RNA疗法,包括非目标效应方面仍然存在挑战.
- 在临床环境中进一步验证对于实现RTK-RNAs的全部潜力至关重要.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Receptor Tyrosine Kinases
13.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.0K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


